Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Sei Investments Co.

Sei Investments Co. decreased its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 9.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 161,682 shares of the company’s stock after selling 17,535 shares during the quarter. Sei Investments Co.’s holdings in Vaxcyte were worth $13,235,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Whipplewood Advisors LLC purchased a new stake in shares of Vaxcyte during the fourth quarter valued at $28,000. Smartleaf Asset Management LLC lifted its position in Vaxcyte by 188.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock worth $33,000 after acquiring an additional 260 shares during the period. Blue Trust Inc. grew its stake in Vaxcyte by 100.0% during the 4th quarter. Blue Trust Inc. now owns 742 shares of the company’s stock valued at $61,000 after purchasing an additional 371 shares during the last quarter. Assetmark Inc. increased its holdings in shares of Vaxcyte by 77,500.0% in the fourth quarter. Assetmark Inc. now owns 776 shares of the company’s stock valued at $64,000 after purchasing an additional 775 shares during the period. Finally, Nomura Asset Management Co. Ltd. purchased a new position in shares of Vaxcyte in the third quarter worth about $92,000. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Insider Transactions at Vaxcyte

In other news, Director Teri Loxam sold 6,250 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total value of $531,937.50. Following the transaction, the director now owns 7,175 shares in the company, valued at $610,664.25. This trade represents a 46.55 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Jim Wassil sold 8,000 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $73.27, for a total value of $586,160.00. Following the sale, the chief operating officer now owns 154,931 shares of the company’s stock, valued at $11,351,794.37. The trade was a 4.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 46,250 shares of company stock valued at $3,840,018 in the last three months. 3.10% of the stock is currently owned by company insiders.

Vaxcyte Stock Performance

Shares of NASDAQ PCVX opened at $69.46 on Friday. The company has a market capitalization of $8.94 billion, a PE ratio of -15.10 and a beta of 1.02. The company’s fifty day moving average price is $80.07 and its 200 day moving average price is $92.68. Vaxcyte, Inc. has a 1 year low of $58.10 and a 1 year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.14. On average, equities analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Guggenheim reiterated a “buy” rating and issued a $160.00 price target on shares of Vaxcyte in a report on Wednesday, March 12th. Needham & Company LLC reiterated a “buy” rating and issued a $140.00 price objective on shares of Vaxcyte in a research note on Wednesday, February 26th. Finally, The Goldman Sachs Group assumed coverage on shares of Vaxcyte in a research report on Friday, December 20th. They set a “buy” rating and a $135.00 target price for the company. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $147.50.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.